Status:
COMPLETED
Safety and Efficacy Maintenance Study of Quetiapine SR to Treat GAD Patients.
Lead Sponsor:
AstraZeneca
Conditions:
Anxiety Disorders
Eligibility:
All Genders
18-65 years
Phase:
PHASE3
Brief Summary
The primary objective of this study is to evaluate the efficacy of quetiapine SR compared to placebo in increasing time from randomisation to an anxiety event in patients with generalised anxiety diso...
Eligibility Criteria
Inclusion
- Patients will be male or female, 18 to 65 years of age (inclusive), with a diagnosis of GAD according to DSM-IV criteria 300.02 as assessed by the MINI.
Exclusion
- Patients suffering from depressive symptoms, defined as having a Montgomery-Åsberg Depression Rating Scale (MADRS) total score of 17 or more at the enrolment visit, will be excluded from participation in this study.
Key Trial Info
Start Date :
March 1 2006
Trial Type :
INTERVENTIONAL
End Date :
August 1 2007
Estimated Enrollment :
575 Patients enrolled
Trial Details
Trial ID
NCT00314210
Start Date
March 1 2006
End Date
August 1 2007
Last Update
March 25 2009
Active Locations (114)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Mesa, Arizona, United States
2
Research Site
Peoria, Arizona, United States
3
Research Site
Phoenix, Arizona, United States
4
Research Site
Fresno, California, United States